According to the World Health Organization, approximately 50 million people have epilepsy globally. It is one of the most common neurological diseases. As per data suggested by the Centers for Disease Control and Prevention, in the United States, 3 million people suffer from epilepsy. There has been a significant emphasis on developing effective seizure therapeutic products for neurological disorders as major companies and institutions are working towards innovative treatments for seizures.
The detailed seizures analytical perspective of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to seizures are covered.
Seizures treatment includes the use of anti-seizure medicines. Different options for anti-seizure medicine are available in the market. Companies are developing innovative treatments to manage seizures. For instance, a phase III clinical trial study is being conducted to assess the effects of ZX008 when used as adjunctive therapy for the treatment of seizures. Several seizure therapeutic products in the pipeline are being developed by major pharma companies which has impacted the pipeline analysis for seizures.
RWJ-333369
A phase III study, sponsored by SK Life Science, Inc. is evaluating the safety and effectiveness of the drug to manage partial epilepsy in patients who have poor seizure control.
This product will be delivered within 3-5 business days.
Report Coverage
The Seizures Drug Pipeline Report by the publisher gives comprehensive insights into seizures drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for seizures. The seizures report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from seizures.The detailed seizures analytical perspective of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to seizures are covered.
Seizures Drug Pipeline Outlook
A seizure is a sudden and uncontrolled burst of electrical activity in the brain, which can cause changes in movements, behavior, and levels of consciousness. It can occur after a head injury or a stroke and be caused by an infection such as meningitis. There are multiple types of seizures. The type of seizure varies from where they begin in the brain. The frequency of most seizures lasts from 30 seconds to two minutes. The symptoms of seizure include temporary confusion, staring spells, jerking movements of the legs and arms, loss of consciousness or awareness, and cognitive changes.Seizures treatment includes the use of anti-seizure medicines. Different options for anti-seizure medicine are available in the market. Companies are developing innovative treatments to manage seizures. For instance, a phase III clinical trial study is being conducted to assess the effects of ZX008 when used as adjunctive therapy for the treatment of seizures. Several seizure therapeutic products in the pipeline are being developed by major pharma companies which has impacted the pipeline analysis for seizures.
Seizures - Drug Pipeline Therapeutic Assessment
This section of the seizures report covers the analysis of seizure drugs based on various segmentations such as:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The seizures clinical assessment of products covers 50+ drug analyses based on drug classes:
- Sodium Channel Blockers
- Calcium Channel Blockers
- Gamma-Aminobutyric Acid (GABA)
- Enhancers Glutamate Receptor Antagonists
By Route of Administration
The seizures clinical assessment covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Seizures - Pipeline Assessment Segmentation, By Phases
The seizures pipeline insight covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials, with approximately 300 trials are currently in phase III.Seizures - Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under seizure pipeline analysis include sodium channel blockers, calcium channel blockers, gamma-aminobutyric acid (GABA), enhancers glutamate receptor antagonists. Sodium channel blockers inhibit voltage-gated sodium channels help in reducing neuronal excitability and prevent the spread of seizure. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for seizures.Seizures Clinical Trials Assessment - Competitive Dynamics
The report for the seizures pipeline landscape covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in seizures clinical trials:- GSK PLC
- Eisai Co., Ltd.
- Novartis AG
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Neurelis, Inc.
- Others
Seizures - Pipeline Drugs Profile
Cannabidiol Oral Solution
Cannabidiol oral solution is currently under phase II and is sponsored by INSYS Therapeutics Inc. The study is being conducted to assess the safety and tolerability of three multiple ascending doses of cannabidiol oral solution in patients.RWJ-333369
A phase III study, sponsored by SK Life Science, Inc. is evaluating the safety and effectiveness of the drug to manage partial epilepsy in patients who have poor seizure control.
Retigabine
GlaxoSmithKline is developing the drug and it is currently under phase III. The study is investigating the safety and efficacy of seizures treatment retigabine dosed at 900 mg/day and 600 mg/day in epilepsy patients.Reasons To Buy This Report
The Seizures Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for seizures. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into seizures collaborations, market trends, regulatory environments, and potential growth opportunities within seizure drug pipeline insights.Key Questions Answered in the Seizures - Pipeline Assessment Report
- What is the current landscape of Seizures pipeline drugs?
- Which companies/institutions are developing Seizures emerging drugs?
- How many phase II drugs are currently present in Seizures pipeline drugs?
- Which company is leading the Seizures pipeline development activities?
- What is the current Seizures therapeutic assessment?
- What are the opportunities and challenges present in the Seizures drug pipeline landscape?
- What is the efficacy and safety profile of Seizures pipeline drugs?
- Which companies/institutions are involved in Seizures collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Seizures?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Seizures
4 Patient Profile
5 Seizures: Epidemiology Snapshot
6 Seizures: Market Dynamics
7 Seizures: Key Facts Covered
8 Seizures, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Seizures Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Seizures Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Seizures Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Seizures Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Seizures, Key Drug Pipeline Companies
